Filter by:

Levin A. The effect of lowering LDL cholesterol on vascular access latency: Post-hoc analysis of the study of heart and renal protection.

February 25, 2015

Herrington W, Emberson J, Staplin N, Blackwell L, Fellstrom B, Walker R, Levin A, Hooi LS, Massy ZA, Tesar V, Reith C, Haynes R, Baigent C, Landray MJ; on behalf of the SHARP Investigators. The effect of lowering LDL cholesterol on vascular access latency: Post-hoc analysis of the study of heart and renal protection. Clin J Am Soc Nephrol. 2014 May;9(5):914-9. doi: 10.2215/CJN.10371013. Epub 2014 Mar 13. PMID: 24626433.

Read More

Levin A. Evaluating the contribution of the cause of kidney disease to prognosis in CKD: Results from the Study of Heart and Renal Protection (SHARP).

February 25, 2015

Haynes R, Staplin N, Emberson J, G Herrington W, Tomson C, Agodoa L, Tesar V, Levin A, Lewis D, Reith C, Baigent C, Landray MJ; SHARP Collaborative Group. Evaluating the contribution of the cause of kidney disease to prognosis in CKD: Results from the Study of Heart and Renal Protection (SHARP). Am J Kidney Dis. 2014 Jul;64(1):40-8. doi: 10.1053/j.ajkd.2013.12.013. Epub 2014 Mar 5. PMID: 24613056.

Read More

Li LC. A proof-of-concept study of ANSWER, a web-based methotrexate decision aid for patients with rheumatoid arthritis.

February 25, 2015

Li LC, Adam PM, Backman CL, Lineker S, Jones CA, Lacaille D, Townsend AF, Yacyshyn E, Yousefi C, Tugwell P, Leese J, Stacey D. A proof-of-concept study of ANSWER, a web-based methotrexate decision aid for patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Oct;66(10):1472-81. doi: 10.1002/acr.22319. Epub 2014 Mar 12. PMID: 24623617.

Read More